Cluster for Individualized ImmunoIntervention (CI-3) Submits Final BMBF “Spitzencluster” Grant Aplication
TRON participates with immunotherapies, centralized service facilities, biomarker research and analysis projects
In competing for one of up to five “leading-edge cluster” awards of the German Federal Ministery of Education and Science (BMBF), the Rhein-Main regional Cluster for Individualized ImmunoIntervention (CI-3) today submitted its final project application. More than 120 regional research organizations, hospitals, biotech and pharmaceutical companies participated in the CI-3 Cluster and submitted more than 80 individual projects focused on innovative immunotherapies and individualized medicine. If selected, the CI-3 cluster will create new high-tech jobs and further develop the critical mass for individualized medicine, immunotherapies and improved healthcare in the Rhein-Main region.
Within the CI-3 Cluster Initiative, TRON offers immunotherapies and translational platforms for cluster participants, extensive analysis and development of bio- and immuno-markers.
“As a dedicated translational center, we support the cluster initiative with our unique multi-disciplinary setup and expertise, says Prof. Dr. Ugur Sahin, Scientific Director of TRON (Translational Oncology at the University Medical Center, Mainz). “We are ready to be part of one of the broadest pipelines worldwide for immunotherapeutic drugs for the treatment of cancer, autoimmune and infectious diseases.”
Among the cluster’s over 120 partners and participants are MerckSerono, Boehringer Ingelheim, Abbot, over 40 small to mediums sized biotech and IT companies, seven regional universities, research institutes such as the Paul-Ehrlich Institute, Fraunhofer ITWM as well as insurance representatives such as AOK Rheinland-Pfalz and non-profit associations like the Association for Cancer Immunotherapy (CIMT) and Krebsforschung Rhein-Main e.V..
“The goal of CI-3 is to establish the Rhine-Main region as an internationally recognized leading center of excellence for individualized immune interventions” says Rainer Wessel, Cluster Management Director. “The quality and innovative spirit of more than 80 submitted CI-3 projects testify to the region’s prowess in a health-industry sector for which one of the highest growth-rates are predicted.”